Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, the personalized, BCMA-directed CAR-T therapy for multiple myeloma being developed under a partnership with Arcellx.

Anito-cel has multibillion-dollar sales potential, if it proves to be competitive on efficacy and safer from a neurotoxicity perspective than Carvykti, the currently approved BCMA CAR-T product from Johnson & Johnson and Legend Biotech. Carvykti is already on a billion-dollar run rate, with a peak sales forecast in the $5-6 billion range, according to Visible Alpha.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

AstraZeneca’s concurrent Imfinzi-chemo-radiation combo in lung cancer misses primary endpoint in PhIII trial

AstraZeneca’s PD-L1 Imfinzi failed a Phase III trial in non-small cell lung cancer (NSCLC) when investigated concurrently with chemoradiotherapy (CRT) as the company worked to

November 15, 2023

Roche’s Columvi receives marketing approval in Europe – Pharmaceutical Technology

Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to treat R/R DLBCL and is given for a fixed time, a maximum of 12 cycles.

July 11, 2023

Cause of Missouri Doc’s Death; NBA Star’s Bell’s Palsy; Huge Data Breach at Kaiser

Note that some links may require registration or subscription. John Forsyth, MD, the Missouri emergency physician whose death last May drew national attention and online

April 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.